28
Oct
2025

Getwell Pharma (I) Pvt Ltd

Exhibitor at CPHI Frankfurt 2025 stand 3.0M14, Finished Dosage Formulations
About Us

 
We consider ourselves " Your Partner in Oncology"

Getwell Pharma is a dedicated manufacturer-exporter of sterile oncology injectables since more than 30 years, our automated modern unit uses isolator fill-finish process and we follow a robust compliance & risk management system.

We offer our products for regulated and semi-regulated markets with strong dossier support.
 
Plz meet us at our stand 1H50 during CPHI Barcelona to discuss out licensing opportunities and tech transfer projects for oncology.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2022
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 3.0M14, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025

  • Albumin bound Paclitaxel inj

    Product Albumin bound Paclitaxel inj

    Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others.
  • Liposomal DOxorubicine inj

    Product Liposomal DOxorubicine inj

    Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. Indication: i) As monotherapy for patients with metastatic breast cancer, where there is an increa...